Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
41
BSX Quote, Financials, Valuation and Earnings
Last price:
$68.56
Seasonality move
:
5.19%
Day range:
$68.19 - $70.40
52-week range:
$67.56 - $109.50
Dividend yield:
0%
P/E ratio:
35.35x
P/S ratio:
5.10x
P/B ratio:
4.20x
Volume:
12.4M
Avg. volume:
18.3M
1-year change:
-27.1%
Market cap:
$101.7B
Revenue:
$20.1B
EPS (TTM):
$1.94
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BSX
Boston Scientific Corp.
|
$5.3B | $0.78 | 11.27% | 75.49% | $103.82 |
|
ABT
Abbott Laboratories
|
$11.8B | $1.49 | 6.14% | 54.88% | $132.64 |
|
BAX
Baxter International, Inc.
|
$2.8B | $0.54 | -0.44% | 26.94% | $21.50 |
|
ISRG
Intuitive Surgical, Inc.
|
$2.8B | $2.27 | 16.31% | 10.87% | $609.82 |
|
RMD
ResMed, Inc.
|
$1.4B | $2.72 | 10.42% | 13.28% | $296.87 |
|
SYK
Stryker Corp.
|
$7.1B | $4.40 | 8.35% | 77.07% | $424.90 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BSX
Boston Scientific Corp.
|
$68.55 | $103.82 | $101.7B | 35.35x | $0.00 | 0% | 5.10x |
|
ABT
Abbott Laboratories
|
$108.14 | $132.64 | $187.9B | 29.09x | $0.63 | 2.22% | 4.27x |
|
BAX
Baxter International, Inc.
|
$18.01 | $21.50 | $9.3B | 167.20x | $0.01 | 2% | 0.82x |
|
ISRG
Intuitive Surgical, Inc.
|
$492.87 | $609.82 | $175B | 62.58x | $0.00 | 0% | 17.76x |
|
RMD
ResMed, Inc.
|
$240.15 | $296.87 | $35B | 23.74x | $0.60 | 0.97% | 6.53x |
|
SYK
Stryker Corp.
|
$345.78 | $424.90 | $132.3B | 41.17x | $0.88 | 0.98% | 5.32x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BSX
Boston Scientific Corp.
|
33.07% | 0.600 | 8.45% | 0.94x |
|
ABT
Abbott Laboratories
|
21.33% | 0.218 | 6.98% | 1.05x |
|
BAX
Baxter International, Inc.
|
61.48% | -0.428 | 99.84% | 1.33x |
|
ISRG
Intuitive Surgical, Inc.
|
0.95% | 0.975 | 0.08% | 3.73x |
|
RMD
ResMed, Inc.
|
11.83% | 0.528 | 2.42% | 2.01x |
|
SYK
Stryker Corp.
|
42.19% | 0.219 | 12.42% | 1.07x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BSX
Boston Scientific Corp.
|
$3.6B | $1.2B | 8.3% | 12.55% | 22.93% | $1B |
|
ABT
Abbott Laboratories
|
$6.1B | $2.4B | 10.13% | 12.91% | 20.68% | $2.6B |
|
BAX
Baxter International, Inc.
|
$870M | $117M | -5.13% | -12.97% | 3.93% | $444M |
|
ISRG
Intuitive Surgical, Inc.
|
$1.9B | $864.3M | 16.53% | 16.59% | 30.16% | $730M |
|
RMD
ResMed, Inc.
|
$867M | $500.3M | 22.22% | 25.44% | 35.16% | $305.2M |
|
SYK
Stryker Corp.
|
$4.5B | $2B | 8.59% | 15.17% | 27.74% | $1.9B |
Boston Scientific Corp. vs. Competitors
-
Which has Higher Returns BSX or ABT?
Abbott Laboratories has a net margin of 12.68% compared to Boston Scientific Corp.'s net margin of 15.71%. Boston Scientific Corp.'s return on equity of 12.55% beat Abbott Laboratories's return on equity of 12.91%.
Company Gross Margin Earnings Per Share Invested Capital BSXBoston Scientific Corp.68.5% $0.45 $36.4B ABTAbbott Laboratories53.5% $1.03 $66.9B -
What do Analysts Say About BSX or ABT?
Boston Scientific Corp. has a consensus price target of $103.82, signalling upside risk potential of 51.45%. On the other hand Abbott Laboratories has an analysts' consensus of $132.64 which suggests that it could grow by 22.66%. Given that Boston Scientific Corp. has higher upside potential than Abbott Laboratories, analysts believe Boston Scientific Corp. is more attractive than Abbott Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings BSXBoston Scientific Corp.25 0 0 ABTAbbott Laboratories16 7 0 -
Is BSX or ABT More Risky?
Boston Scientific Corp. has a beta of 0.688, which suggesting that the stock is 31.155% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.741, suggesting its less volatile than the S&P 500 by 25.919%.
-
Which is a Better Dividend Stock BSX or ABT?
Boston Scientific Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 2.22% to investors and pays a quarterly dividend of $0.63 per share. Boston Scientific Corp. pays -- of its earnings as a dividend. Abbott Laboratories pays out 64.54% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BSX or ABT?
Boston Scientific Corp. quarterly revenues are $5.3B, which are smaller than Abbott Laboratories quarterly revenues of $11.5B. Boston Scientific Corp.'s net income of $670M is lower than Abbott Laboratories's net income of $1.8B. Notably, Boston Scientific Corp.'s price-to-earnings ratio is 35.35x while Abbott Laboratories's PE ratio is 29.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific Corp. is 5.10x versus 4.27x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BSXBoston Scientific Corp.5.10x 35.35x $5.3B $670M ABTAbbott Laboratories4.27x 29.09x $11.5B $1.8B
-
Which has Higher Returns BSX or BAX?
Baxter International, Inc. has a net margin of 12.68% compared to Boston Scientific Corp.'s net margin of -34.8%. Boston Scientific Corp.'s return on equity of 12.55% beat Baxter International, Inc.'s return on equity of -12.97%.
Company Gross Margin Earnings Per Share Invested Capital BSXBoston Scientific Corp.68.5% $0.45 $36.4B BAXBaxter International, Inc.29.25% -$2.16 $15.9B -
What do Analysts Say About BSX or BAX?
Boston Scientific Corp. has a consensus price target of $103.82, signalling upside risk potential of 51.45%. On the other hand Baxter International, Inc. has an analysts' consensus of $21.50 which suggests that it could grow by 19.38%. Given that Boston Scientific Corp. has higher upside potential than Baxter International, Inc., analysts believe Boston Scientific Corp. is more attractive than Baxter International, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BSXBoston Scientific Corp.25 0 0 BAXBaxter International, Inc.2 13 1 -
Is BSX or BAX More Risky?
Boston Scientific Corp. has a beta of 0.688, which suggesting that the stock is 31.155% less volatile than S&P 500. In comparison Baxter International, Inc. has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.817%.
-
Which is a Better Dividend Stock BSX or BAX?
Boston Scientific Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International, Inc. offers a yield of 2% to investors and pays a quarterly dividend of $0.01 per share. Boston Scientific Corp. pays -- of its earnings as a dividend. Baxter International, Inc. pays out 180.98% of its earnings as a dividend.
-
Which has Better Financial Ratios BSX or BAX?
Boston Scientific Corp. quarterly revenues are $5.3B, which are larger than Baxter International, Inc. quarterly revenues of $3B. Boston Scientific Corp.'s net income of $670M is higher than Baxter International, Inc.'s net income of -$1B. Notably, Boston Scientific Corp.'s price-to-earnings ratio is 35.35x while Baxter International, Inc.'s PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific Corp. is 5.10x versus 0.82x for Baxter International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BSXBoston Scientific Corp.5.10x 35.35x $5.3B $670M BAXBaxter International, Inc.0.82x 167.20x $3B -$1B
-
Which has Higher Returns BSX or ISRG?
Intuitive Surgical, Inc. has a net margin of 12.68% compared to Boston Scientific Corp.'s net margin of 27.89%. Boston Scientific Corp.'s return on equity of 12.55% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.
Company Gross Margin Earnings Per Share Invested Capital BSXBoston Scientific Corp.68.5% $0.45 $36.4B ISRGIntuitive Surgical, Inc.66.41% $2.21 $18.1B -
What do Analysts Say About BSX or ISRG?
Boston Scientific Corp. has a consensus price target of $103.82, signalling upside risk potential of 51.45%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $609.82 which suggests that it could grow by 23.73%. Given that Boston Scientific Corp. has higher upside potential than Intuitive Surgical, Inc., analysts believe Boston Scientific Corp. is more attractive than Intuitive Surgical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BSXBoston Scientific Corp.25 0 0 ISRGIntuitive Surgical, Inc.17 9 1 -
Is BSX or ISRG More Risky?
Boston Scientific Corp. has a beta of 0.688, which suggesting that the stock is 31.155% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.658, suggesting its more volatile than the S&P 500 by 65.814%.
-
Which is a Better Dividend Stock BSX or ISRG?
Boston Scientific Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific Corp. pays -- of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BSX or ISRG?
Boston Scientific Corp. quarterly revenues are $5.3B, which are larger than Intuitive Surgical, Inc. quarterly revenues of $2.9B. Boston Scientific Corp.'s net income of $670M is lower than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, Boston Scientific Corp.'s price-to-earnings ratio is 35.35x while Intuitive Surgical, Inc.'s PE ratio is 62.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific Corp. is 5.10x versus 17.76x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BSXBoston Scientific Corp.5.10x 35.35x $5.3B $670M ISRGIntuitive Surgical, Inc.17.76x 62.58x $2.9B $799.5M
-
Which has Higher Returns BSX or RMD?
ResMed, Inc. has a net margin of 12.68% compared to Boston Scientific Corp.'s net margin of 27.59%. Boston Scientific Corp.'s return on equity of 12.55% beat ResMed, Inc.'s return on equity of 25.44%.
Company Gross Margin Earnings Per Share Invested Capital BSXBoston Scientific Corp.68.5% $0.45 $36.4B RMDResMed, Inc.60.93% $2.68 $7.2B -
What do Analysts Say About BSX or RMD?
Boston Scientific Corp. has a consensus price target of $103.82, signalling upside risk potential of 51.45%. On the other hand ResMed, Inc. has an analysts' consensus of $296.87 which suggests that it could grow by 23.87%. Given that Boston Scientific Corp. has higher upside potential than ResMed, Inc., analysts believe Boston Scientific Corp. is more attractive than ResMed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BSXBoston Scientific Corp.25 0 0 RMDResMed, Inc.8 7 1 -
Is BSX or RMD More Risky?
Boston Scientific Corp. has a beta of 0.688, which suggesting that the stock is 31.155% less volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.877, suggesting its less volatile than the S&P 500 by 12.278%.
-
Which is a Better Dividend Stock BSX or RMD?
Boston Scientific Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed, Inc. offers a yield of 0.97% to investors and pays a quarterly dividend of $0.60 per share. Boston Scientific Corp. pays -- of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. ResMed, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BSX or RMD?
Boston Scientific Corp. quarterly revenues are $5.3B, which are larger than ResMed, Inc. quarterly revenues of $1.4B. Boston Scientific Corp.'s net income of $670M is higher than ResMed, Inc.'s net income of $392.6M. Notably, Boston Scientific Corp.'s price-to-earnings ratio is 35.35x while ResMed, Inc.'s PE ratio is 23.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific Corp. is 5.10x versus 6.53x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BSXBoston Scientific Corp.5.10x 35.35x $5.3B $670M RMDResMed, Inc.6.53x 23.74x $1.4B $392.6M
-
Which has Higher Returns BSX or SYK?
Stryker Corp. has a net margin of 12.68% compared to Boston Scientific Corp.'s net margin of 11.84%. Boston Scientific Corp.'s return on equity of 12.55% beat Stryker Corp.'s return on equity of 15.17%.
Company Gross Margin Earnings Per Share Invested Capital BSXBoston Scientific Corp.68.5% $0.45 $36.4B SYKStryker Corp.62.81% $2.20 $38.8B -
What do Analysts Say About BSX or SYK?
Boston Scientific Corp. has a consensus price target of $103.82, signalling upside risk potential of 51.45%. On the other hand Stryker Corp. has an analysts' consensus of $424.90 which suggests that it could grow by 22.88%. Given that Boston Scientific Corp. has higher upside potential than Stryker Corp., analysts believe Boston Scientific Corp. is more attractive than Stryker Corp..
Company Buy Ratings Hold Ratings Sell Ratings BSXBoston Scientific Corp.25 0 0 SYKStryker Corp.13 8 0 -
Is BSX or SYK More Risky?
Boston Scientific Corp. has a beta of 0.688, which suggesting that the stock is 31.155% less volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.853, suggesting its less volatile than the S&P 500 by 14.663%.
-
Which is a Better Dividend Stock BSX or SYK?
Boston Scientific Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker Corp. offers a yield of 0.98% to investors and pays a quarterly dividend of $0.88 per share. Boston Scientific Corp. pays -- of its earnings as a dividend. Stryker Corp. pays out 40.48% of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BSX or SYK?
Boston Scientific Corp. quarterly revenues are $5.3B, which are smaller than Stryker Corp. quarterly revenues of $7.2B. Boston Scientific Corp.'s net income of $670M is lower than Stryker Corp.'s net income of $849M. Notably, Boston Scientific Corp.'s price-to-earnings ratio is 35.35x while Stryker Corp.'s PE ratio is 41.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific Corp. is 5.10x versus 5.32x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BSXBoston Scientific Corp.5.10x 35.35x $5.3B $670M SYKStryker Corp.5.32x 41.17x $7.2B $849M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 29x
Alerts
Buy
52
PZZA alert for Mar 12
Papa John's International, Inc. [PZZA] is down 7.08% over the past day.
Buy
53
NBIS alert for Mar 12
Nebius Group NV [NBIS] is down 3.56% over the past day.
Buy
88
NBTX alert for Mar 12
Nanobiotix SA [NBTX] is down 4.42% over the past day.
